Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Regeneron Pharmaceuticals (NQ: REGN )

843.60 +5.40 (+0.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
41 42 Next >
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
Stock Market Rally Falls As Fed Signals More Big Rate Hikes; Salesforce, Tesla In Focus: Weekly Review
Stocks fell modestly on hawkish Fed comments, but the Nasdaq held its 21-day line. 
Via Investor's Business Daily
Markets Rise Amid Strength In Tech, Software
U.S. indices finished Thursday’s trading session higher. Overall tech and software sector strength as well as strong first-quarter results from Mongodb Inc (NASDAQ: MDB) lifted markets higher for the... 
Via Benzinga
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
The U.S. 
Via Benzinga
Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years
Via Benzinga
How Regeneron Pharmaceuticals Beat Quarterly Projections Without Leaning On Covid
Excluding the company's Covid antibody, sales surged 25% and still topped forecasts. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer
Regeneron secured the global rights to Sanofi-partnered Libtayo. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 11 strange... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
7 Analysts Have This to Say About Regeneron Pharmaceuticals
Over the past 3 months, 7 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Here's Why This Analyst Cut Price Target On Regeneron
Via Benzinga
NASDAQ:REGN Investor Notice: Investigation over Potential Wrongdoing at Regeneron Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 05/31/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Regeneron Pharmaceuticals, Inc. 
Via SBWire
As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats
The COVID-19 pandemic that emerged in early 2020 doesn't seem to have run its course. Daily average cases, though have declined notably, stood at 110,084 in the U.S. as of Thursday, according to data... 
Via Benzinga
United Airlines Leads Five Stocks Breaking Resistance As Market Rebounds
United Airlines headlines five stocks to watch for the week ahead. 
Via Investor's Business Daily
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc. 
Via Benzinga
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses? 
Via Investor's Business Daily
Gilead Stock Earns Rating Upgrade After Quick Turnaround
A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue? 
Via Investor's Business Daily
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Regeneron Pharmaceuticals Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q1 earnings of $973.50 million, an increase from Q4 of 56.33%. Sales dropped to $2.96 billion, a 40.13% decrease between... 
Via Benzinga
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
The race is on in eczema treatment as the biggest name faces new rivals. 
Via Investor's Business Daily
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97. 
Via Investor's Business Daily
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
Lithium plays jump on earnings, but Nasdaq at lowest level since 2020. 
Via Investor's Business Daily
$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 19.7%. Currently, Regeneron... 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Regeneron Pharmaceuticals: Q1 Earnings Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Preview: Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter: 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
41 42 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.